RAAS antagonists dampen the SARS-CoV-2 infection in ex-vivo cultured human precision-cut lung slices
RAAS-antagonizing drugs do not seem to exert detrimental effects during SARS-CoV-2 infection. In opposite, in an ex-vivo model of human PCLS, such treatment was found to dampen SARS-CoV-2 infection and consecutive inflammation.
Authors
- Susanne Herold (ORCID: https://orcid.org/0000-0001-6343-0911)
- Christin Müller (ORCID: https://orcid.org/0000-0002-6444-9478)
- Peter Dorfmüller (ORCID: https://orcid.org/0000-0003-2499-6829)
- Stefanie Dimmeler (ORCID: https://orcid.org/0000-0002-1045-2436)
- Ekaterina Krauss (ORCID: https://orcid.org/0000-0001-8682-4294)
- John Ziebuhr (ORCID: https://orcid.org/0000-0002-5741-8825)
- Clemens Ruppert (ORCID: https://orcid.org/0000-0002-0938-2469)
- Martina Korfei (ORCID: https://orcid.org/0000-0001-8177-2085)
- Savério Bellusci (ORCID: https://orcid.org/0000-0001-5987-4579)
- Biruta Witte (ORCID: https://orcid.org/0000-0002-4214-4948)
- Stefan Gattenloehner
- Andreas Guenther
- Elie El Agha
- Poornima Mahavadi
Institutions
- Goethe University Frankfurt (DE)
- Ipsen (France) (FR)
- Justus-Liebig-Universität Gießen (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- Frankfurt Institute for Advanced Studies (DE)
- German Center for Infection Research (DE)
- Universities of Giessen and Marburg Lung Center (DE)
- Giessen School of Theology (DE)
- Evangelische Kliniken Gelsenkirchen (DE)
- Cardio-Pulmonary Institute (DE)
Publication Details
- Journal
- Respiratory Research
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1186/s12931-025-03463-8
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00